Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Fortis Healthcare Limited — Q3 FY26
Fortis Healthcare delivered a strong Q3 FY26 with consolidated revenue of INR 2,265 crore (+17.5% YoY) and EBITDA margin expansion of 290 bps to 22.3%, driven by hospital business growth of 19.4% and diagnostic margin recovery.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Fortis Healthcare delivered a strong Q3 FY26 with consolidated revenue of INR 2,265 crore (+17.5% YoY) and EBITDA margin expansion of 290 bps to 22.3%, driven by hospital business growth of 19.4% and diagnostic margin recovery. Hospital ARPOB rose 4.5% to INR 2.56 crore, supported by a 52% surge in robotic surgeries. Occupied beds grew 14% to 3,189, while occupancy held at 67%. The diagnostics business (Agilus) saw EBITDA margins improve to 23.1% from 14.4% YoY. Management guided for continued margin improvement via brownfield expansions (400+ beds next year, including FMRI) and cluster-based M&A (People Tree acquisition in Bengaluru). Risks include integration challenges at Gleneagles (negative 9M revenue growth) and potential dilution from IHH equity infusion.
फोर्टिस हेल्थकेयर ने तीसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 2,265 करोड़ रुपये रही, जो पिछले साल से 17.5% ज्यादा है। मुनाफा बढ़ाने की क्षमता (EBITDA मार्जिन) 22.3% हो गई, जो पहले 19.4% थी। अस्पतालों का कारोबार 19.4% बढ़ा और जांच सेवाओं (डायग्नोस्टिक्स) का मुनाफा सुधरा। हर बिस्तर से कमाई 4.5% बढ़कर 2.56 करोड़ रुपये हुई, क्योंकि रोबोटिक सर्जरी में 52% उछाल आया। कब्जे वाले बिस्तर 14% बढ़कर 3,189 हो गए, लेकिन भराव दर 67% पर स्थिर रही। जांच कारोबार (एगिलस) का मुनाफा 14.4% से बढ़कर 23.1% हो गया। कंपनी नए अस्पताल खोलकर और छोटी कंपनियां खरीदकर मुनाफा और बढ़ाने की योजना बना रही है। जोखिमों में ग्लेनीगल्स का कमजोर प्रदर्शन और आईएचएच से निवेश से हिस्सेदारी कमजोर होना शामिल है।
Promises0 met · 2 missedRisks3 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
3 risks
Risk Intelligence
Gleneagles O&M integration challenges
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Hospital ARPOB
INR 2.56 Cr
+4.5% YoY
Average revenue per occupied bed per annum, driven by case mix and price increases.
Occupied Beds
3,189
+14% YoY
Total occupied beds in Q3, reflecting both organic growth and acquisitions.
Robotic Surgeries Growth
52%
+52% YoY
Year-on-year increase in robotic surgeries, indicating higher complexity cases.
Diagnostics EBITDA Margin
23.1%
+870 bps YoY
Agilus Diagnostics EBITDA margin improved sharply from 14.4% in Q3 FY25.
What Changed vs Last Quarter
NEW
Brownfield bed addition of 400+ beds in FY27
Targeting over 400 brownfield beds next year, primarily from FMRI expansion (200 beds) and other facilities.
NEW
ARPOB growth of 4-5% expected for next two years
Management expects ARPOB to grow 4-5% annually, driven by case mix and price increases.
NEW
IHH equity infusion likely in 3-6 months
IHH may infuse fresh equity via preferential allotment to strengthen balance sheet for growth.
DROPPED
Hospital EBITDA margin to exceed initial guidance of 20.5-22.5%
Management indicated possibility of higher margin improvement than guided at the beginning of the year, driven by ramp-up of new units.
DROPPED
Organic bed addition of 400-500 beds in FY26
Company added 550 operational beds in H1 FY26 and expects full-year addition of 400-500 beds.
DROPPED
Diagnostics EBITDA margin of 23-24% for full year FY26
Agilus CFO guided margins to be around 23-24% for the full year, based on H1 performance of 24%.
DROPPED
ARPOB growth of 5-6% in H2 FY26
Management expects ARPOB growth of 5-6% in second half, driven by mix improvement and robotic surgeries.
NEW RISK
Intense competition in Hyderabad cluster
Management noted intense competition in Hyderabad, making M&A there less attractive.
NEW RISK
Occupancy drag from new units
New facilities like Greater Noida and Adayu dragged overall occupancy by ~50 bps.
RISK GONE
CGHS payment uncertainty and policy changes
Management expressed caution on CGHS due to non-predictability of payments and potential circular changes, despite recent rate increases.
RISK GONE
Debt increase from acquisitions
Net debt rose to INR 2,219 crore (0.96x EBITDA) from 0.16x a year ago due to acquisitions, though management is comfortable.
RISK GONE
Delay in SMRI capacity addition
Commissioning of 225 beds at SMRI delayed by three months to March 2026, pushing revenue contribution to next fiscal.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q1 FY26, Q2 FY25, Q3 FY25
Management reiterated guidance of 200 bps margin expansion for the hospital business in FY26, supported by case mix improvement and operational efficiencies.
Mentioned in Q2 FY26, Q4 FY25
Management expects ARPOB growth of 5-6% in second half, driven by mix improvement and robotic surgeries.
Mentioned in Q1 FY25, Q3 FY25
Agilus expects to return to industry-level growth of 8-10% by Q2 FY26, driven by volume growth.
Mentioned in Q3 FY25, Q4 FY25
Despite margin improvement, Agilus revenue growth has been low single-digit; management's double-digit growth target may be challenged by competitive pressures.
Mentioned in Q1 FY25, Q4 FY25
Legal and other legacy costs continue to consume ~1% of EBITDA, with no near-term resolution expected for the Delhi High Court case.
Fast read
Guidance and risk preview
Targeting over 400 brownfield beds next year, primarily from FMRI expansion (200 beds) and other facilities.
Gleneagles revenue declined 4% in 9M due to clinician attrition and management changes; turnaround uncertain.
View Risks →